Beyond the patent cliff: Legal challenges and growth opportunities for life sciences companies

Patent expiries are transforming big pharma and life sciences deal-making, from M&A and licensing to collaboration and investment strategies. As blockbuster products approach the patent cliff, businesses face both real risk and significant opportunity.

We are delighted to be joined by Jonathan Falconer, Executive Director of Legal (M&A, Corporate Transactions Lead) at BioNTech, and Alexander Spicer, M&A Associate at SERB Pharmaceuticals, for a practical discussion on how to:

• Plan proactively for loss of exclusivity and protect market position
• Adapt portfolio and growth strategies in response to looming patent expiries
• Use deals (M&A, licensing, collaborations, minority stakes) to drive innovation and maximise asset value
• Navigate regulatory and IP complexities when structuring and executing transactions.